MMV receives sustained funding and support from government agencies, private foundations, international organizations, corporations, corporate foundations and private individuals. These funds are used to finance MMV’s portfolio of R&D projects as well as specific, targeted access and delivery interventions that aim to make it easier for vulnerable populations to access MMV products.
Since its foundation in 1999, MMV has spent USD 778 million to build the world’s largest R&D portfolio of new and innovative antimalarial medicines. With partners, MMV has brought forward six new antimalarials and distributed millions of treatments that are saving lives. Our business plan estimates a minimum of USD 420 million will be required over the period 2017–2021 to sustain our work.
Progress in research is dependent on funding. With approximately USD 220 million available, (USD 181 million outstanding committed pledges at the end of 2016, as well as USD 42 million cash brought forward to 2017), the organization is currently tracking a project budget gap of approximately USD 200 million between 2019 and 2021. To overcome this, MMV is striving to expand and develop current and new donors and negotiate the best terms with our partners.
Total funding received/pledged from 1999 to 2021
USD 976 million as at 31 December 2016
MMV expenditure 2016 – Total: USD 68.5 million
MMV income and expenditure to date and scenario 201–2021
More details are available in the Financial Section of our Annual Report.